nmCRPC

0:05:52

Meeting patient needs: Understanding nmCRPC treatment options

1:07:50

UROwebinar: Management of nmCRPC: Putting current evidence

0:09:01

PSMA-PET disease extent and overall survival in nmCRPC patients

0:06:13

Ep. 7: Current Treatment and Imaging Options for nmCRPC

0:02:50

The Differences Between mCRPC and nmCRPC

0:02:38

Safety outcomes of darolutamide vs apalutamide and enzalutamide in nmCRPC

0:02:50

PROSPER: Enzalutamide vs. placebo for nmCRPC

0:03:00

Emerging Treatment for nmCRPC

0:02:17

Dr Morgans on the Importance of Detecting Radiographic Progression in nmCRPC

0:15:49

ADT Resistant Non-Metastatic Prostate Cancer (nmCRPC) - 2021 Prostate Cancer Patient Conference

0:01:31

SPARTAN vs. PROSPER: apalutamide or enzalutamide for nmCRPC?

0:03:19

Live long and PROSPER: enzalutamide for nmCRPC

0:02:25

Advances in nmCRPC

0:37:26

nmCRPC made easy!! Who, when and how

0:01:55

Awaiting key results for enzalutamide and apalutamide in nmCRPC

0:01:38

nmCRPC: Therapy Evolution and Future

0:51:05

UROwebinar: Management of nmCRPC: Putting current evidence into practice

0:02:46

ARAMIS: darolutamide in patients with nmCRPC

0:01:57

ARAMIS: efficacy and safety of darolutamide in nmCRPC

0:03:38

The NCCN and AUA Guidelines for Treating nmCRPC

0:15:23

ARAMIS Follow-Up: PSA Levels, Radiological Progression in nmCRPC

1:05:22

UROwebinar: Imaging and PSA assessment in nmCRPC patients and the treatment consequences

0:08:22

Ep. 9: Neurological AEs and Quality of Life in Treating nmCRPC

0:03:06

How AR Therapy Has Changed the nmCRPC Treatment Landscape